Few topics have demanded as much regulatory attention in recent years as nitrosamine impurities. What began as a handful of high-profile recalls became an industry-wide expectation that every marketing authorization holder assess, and where necessary control, the risk. This article sets nitrosamines in the broader context of a modern impurity control strategy.
Why nitrosamines changed the conversation
Nitrosamines are potent mutagenic impurities — some carcinogenic at very low levels. Their emergence as a systemic issue forced two realizations: that impurities can arise from unexpected sources across the synthetic route and supply chain, and that a reactive, case-by-case approach is inadequate. Regulators now expect a structured, risk-based control strategy.
The nitrosamine experience is, in effect, a stress test of impurity control discipline that applies far more broadly.
The framework: ICH M7 and Q3
A modern impurity control strategy rests on established ICH guidance:
- ICH M7 governs assessment and control of mutagenic (DNA-reactive) impurities, including the threshold of toxicological concern and control approaches. Nitrosamines fall squarely here.
- ICH Q3A/B/C/D cover organic impurities, degradation products, residual solvents and elemental impurities respectively.
- ICH Q11 addresses development and manufacture of drug substances, including the rationale for the control strategy.
Together these define how impurities should be identified, assessed, controlled and justified.
A three-step discipline
Whether for nitrosamines or any impurity class, the control discipline is consistent:
- Map the sources. Trace every credible route by which the impurity could form or be introduced — starting materials, reagents, solvents, catalysts, degradation, packaging, even recovered materials and cross-contamination.
- Assess the risk. Evaluate likelihood and toxicological relevance, deriving limits where needed (for mutagens, against the M7 framework).
- Define and justify controls. Establish control points, analytical methods and specifications, and document the rationale that ties limits to thresholds and batch data.
Nitrosamine-specific lessons
The nitrosamine work surfaced lessons worth generalizing:
- Look beyond the obvious. Nitrosamines arose not only from known reagents but from secondary and tertiary amines, recovered solvents and supplier processes — sources easy to miss without a systematic search.
- The supply chain is in scope. Impurity risk does not stop at your factory gate; supplier processes and materials must be assessed.
- Analytical capability matters. Controlling impurities at very low limits demands sensitive, validated methods — a frequent practical bottleneck.
Justification is half the job
Identifying and controlling an impurity is only part of the requirement; regulators expect a documented justification of specifications. Every reported and specified impurity should be characterized, qualified against thresholds and batch data, and defensible under review. A control strategy without a clear justification narrative invites queries.
From reactive to designed-in
The strategic shift the industry is making is from reacting to impurity surprises toward designing control in from development. Building impurity assessment into route design, supplier selection and the control strategy — rather than discovering problems late — is both more efficient and more robust.
The takeaway
Nitrosamines were a warning that impurity control cannot be casual. A modern strategy — source mapping, risk-based assessment against ICH M7 and Q3, defensible limits and clear justification — protects patients, satisfies regulators, and turns a recurring source of crises into a managed, designed-in discipline.
PharmExpert develops impurity control strategies and justifications — including mutagenic and nitrosamine risk — and derives toxicological limits. Explore our Product Development services.